Anacor Pharmaceuticals Reports First Quarter 2013 Financial Results

  Anacor Pharmaceuticals Reports First Quarter 2013 Financial Results

Business Wire

PALO ALTO, Calif. -- May 09, 2013

Anacor Pharmaceuticals (NASDAQ:ANAC) announced today its financial results for
the first quarter ended March 31, 2013.

“It was an eventful first quarter. We reported positive data from our two
Phase 3 trials of tavaborole in onychomycosis, and we are on track to file our
NDA around the middle of this year. In addition, we reported successful
results from our third Phase 2 trial of AN2728 in atopic dermatitis, which
informed the most efficacious dosing regimen for our anticipated Phase 3
trials,” said David Perry, Chief Executive Officer of Anacor Pharmaceuticals.
“And most recently, we accomplished the goal of our previously scheduled
preliminary injunction hearing as Valeant agreed not to launch efinaconazole,
its topical product candidate for onychomycosis, if approved, until after our
final arbitration hearing in September of this year.”

First Quarter 2013 Highlights and Recent Developments


  *Tavaborole – our lead topical antifungal product candidate for the
    treatment of onychomycosis, a fungal infection of the nail and nail bed
    that affects approximately 35 million people in the United States.

       *In the first quarter of 2013, we announced the results from two Phase
         3 clinical trials in which tavaborole achieved statistically
         significant and clinically meaningful results on all primary and
         secondary endpoints.

  *AN2728 – our lead topical anti-inflammatory product candidate for the
    treatment of atopic dermatitis and psoriasis. Atopic dermatitis is a
    chronic rash characterized by inflammation and itching and affects an
    estimated 40 million people in the seven major pharmaceutical markets,
    including approximately 10% to 20% of infants and young children.

       *In March 2013, we announced positive results from a Phase 2
         dose-ranging trial of AN2728 in adolescents (ages 12 – 17) with
         mild-to-moderate atopic dermatitis. This was our third Phase 2 study
         of AN2728 in atopic dermatitis. A clear dose response was
         demonstrated in this study, with AN2728 ointment, 2.0% BID yielding
         the greatest improvement, and AN2728 continued to demonstrate an
         excellent safety profile.

Research Agreement

On April 5, 2013, we entered into a research agreement with the Bill & Melinda
Gates Foundation (the Gates Foundation) to discover drug candidates intended
to treat two filarial worm diseases (onchocerciasis, or river blindness, and
lymphatic filariasis, commonly known as elephantiasis) and tuberculosis. Under
the agreement, the Gates Foundation will pay Anacor up to $17.7 million over a
three-year term to conduct research activities directed at discovering
potential drug candidates for these neglected diseases. In addition, the Gates
Foundation purchased shares of Anacor’s common stock for net proceeds of
approximately $5.0 million.


  *In May 2013, we completed an underwritten public offering of 3,599,373
    shares of our common stock, including the exercise of the overallotment
    option in full by the underwriters, for net proceeds of approximately
    $21.4 million.
  *In May 2013, Valeant Pharmaceuticals International, Inc. (Valeant) agreed
    that the launch of efinaconazole, its topical product candidate for the
    treatment of onychomycosis, will not occur, if at all, until after the
    September 2013 arbitration hearing to resolve the breach of contract
    dispute we initiated with them in October 2012. As a result, the
    preliminary injunction hearing, which was previously scheduled for May
    6-8, 2013, was canceled.

Anticipated Milestones in the Next Twelve Months

  *Tavaborole, our lead product candidate for the treatment of onychomycosis:

       *We expect to file a New Drug Application with the FDA for tavaborole
         in mid-2013.
       *We currently have a final hearing for our arbitration with Valeant
         scheduled in September 2013 and anticipate the resolution of the
         arbitration in the second half of 2013.
       *We expect to choose a path for commercialization of tavaborole in the
         second half of 2013.

  *AN2728, our lead product candidate for the treatment of atopic dermatitis:

       *We expect to initiate the following two additional safety studies
         prior to initiating a Phase 3 study in atopic dermatitis:
         1. MUSE (maximal use systemic exposure) study in ~ 30 children with
         atopic dermatitis to measure blood levels when AN2728 is applied
         under maximal use conditions.
         2. TQT (thorough QT) study to assess the effects of AN2728 on
         electrocardiograms (ECGs) in ~180 healthy volunteers following
         multiple-dose administration.
       *We expect to initiate a Phase 3 study in atopic dermatitis in the
         fourth quarter of 2013 or the first quarter of 2014, with timing
         dependent on the completion of the MUSE study.

Selected First Quarter 2013 Financial Results

Revenues for the quarter ended March 31,  2013 were $1.7 million, compared to
$2.4 million for the comparable period in 2012. The decrease in revenues from
2012 is primarily due to a decrease in research work performed under our
research and development agreements, including agreements with not-for-profit
organizations for neglected diseases. In addition, in the first quarter of
2013, we did not recognize any revenue from the upfront free received in 2011
under the agreement with Medicis relating to the discovery of potential
treatments for acne.

Research and development expenses were $11.2 million for the first quarter of
2013, compared to $12.7 million for the same quarter in 2012. The decrease in
research and development expenses from 2012 is comprised of a decrease in
clinical expenses for tavaborole and a decrease in research and development
related to the Medicis collaboration, partially offset by increases in
expenses related to our Lilly animal health programs and other research

General and administrative expenses for the first quarter of 2013 were $4.7
million, compared to $3.4 million for the comparable period in 2012. The
increase from 2012 is primarily due to an increase in legal fees resulting
from the legal proceedings for our disputes with Valeant.

Cash, cash equivalents and short-term investments totaled $32.4 million at
March 31, 2013, compared to $45.5 million at December 31, 2012.

2013 Financial Outlook

We believe that our existing capital resources, including the net proceeds
from the sale of our common stock in the Gates Foundation private placement
offering in April 2013 and the public stock offering in May 2013, will be
sufficient to meet our anticipated operating requirements until at least the
end of 2013.

Conference Call and Webcast

Anacor will host a conference call at 5:00 p.m. ET / 2:00 p.m. PT today,
during which management will discuss the Company’s financial results and
recent developments. The call can be accessed by dialing (877) 291-1367
(domestic) and (914) 495-8534 (international) five minutes prior to the start
of the call. The call will also be webcast live and can be accessed on the
Events and Presentations page, under Investors, on the Company’s website at and will be available for three months following the call.

About Anacor Pharmaceuticals

Anacor is a biopharmaceutical company focused on discovering, developing and
commercializing novel small-molecule therapeutics derived from its boron
chemistry platform. Anacor has discovered eight compounds that are currently
in development. Its two lead product candidates are topically administered
dermatologic compounds — tavaborole, an antifungal for the treatment of
onychomycosis, and AN2728, an anti-inflammatory PDE-4 inhibitor for the
treatment of atopic dermatitis and psoriasis. In addition to its two lead
programs, Anacor has discovered three other wholly-owned clinical product
candidates — AN2718 and AN2898, which are backup compounds to tavaborole and
AN2728, respectively, and AN3365 (formerly referred to as GSK2251052, or
GSK‘052), an antibiotic for the treatment of infections caused by
Gram-negative bacteria, which previously was licensed to GlaxoSmithKlineLLC,
or GSK. GSK has returned all rights to the compound to us and we are
considering our options for further development, if any, of this compound. We
have also discovered three other compounds that we have out-licensed for
further development — two are licensed to Eli Lilly and Company for the
treatment of animal health indications and the third compound, AN5568, also
referred to as SCYX-7158, is licensed to Drugs for Neglected Diseases
initiative, or DNDi, for human African trypanosomiasis (HAT, or sleeping
sickness). We also have a pipeline of other internally discovered topical and
systemic boron-based compounds in development. For more information, visit

Forward-Looking Statements

This release contains forward-looking statements, including statements
regarding our milestones, clinical plans and financial projections.Our actual
results may differ materially from those indicated in these forward-looking
statements due to risks and uncertainties, including the timing of filing of
our NDA for tavaborole; the timing and potential outcome of our arbitration
with Valeant; the timing of data from our safety studies and the initiation of
a Phase 3 study for AN2728; risks relating to patient accrual and execution on
clinical plans; the potential for success of tavaborole and our AN2728
compound; the size of the markets in onychomycosis, atopic dermatitis and
psoriasis; the decision and timing of any further development of AN3365;
financial projections related to our cash balance and use of cash as well as
our ability to fund operations as currently conducted beyond the end of 2013;
and other matters that are described in Anacor’s Annual Report on Form 10-K
for the year ended December 31, 2012 filed with the Securities and Exchange
Commission, including the risk factors set forth in that filing. Investors are
cautioned not to place undue reliance on these forward-looking statements,
which speak only as of the date of this release and we undertake no obligation
to update any forward-looking statement in this press release.



(in thousands, except share and per share data)
                                                Three Months Ended March 31,
                                                2013             2012
Contract revenue                                $   1,708         $  2,417
Total revenues                                  1,708             2,417
Operating expenses:
Research and development (1)                    11,159            12,668
General and administrative (1)                  4,716             3,430
Total operating expenses                        15,875            16,098
Loss from operations                            (14,167      )    (13,681    )
Interest income                                 14                21
Interest expense                                (911         )    (654       )
Other expense                                   (14          )    (13        )
Net loss                                        $   (15,078  )    $  (14,327 )
Net loss per common share — basic and diluted   $   (0.42    )    $  (0.48   )
Weighted-average number of common shares used
in calculating net loss per common share —      35,846,287        29,907,348
basic and diluted
(1) Includes the following noncash,
stock-based compensation expenses:
Research and development expenses               $425              $478
General and administrative expenses             334               480



(in thousands)
                                March 31,                  December 31,
                                    2013                     2012 (1)   
Cash, cash equivalents and      $    32,376                $    45,516
short-term investments
Total assets                         37,378                     51,071
Notes payable                        23,516                     25,667
Accumulated deficit                  (230,289    )              (215,211   )
Total stockholders’ equity           (7,975      )              4,811
(1)Derived from the audited financial statements included in the Company’s
Annual Report on Form 10-K for the year ended December 31, 2012.


Anacor Pharmaceuticals, Inc.
Geoff Parker, 650-543-7516
Chief Financial Officer
DeDe Sheel, 650-543-7575
Director, Investor Relations and Corporate Communications
Press spacebar to pause and continue. Press esc to stop.